872973-93-8Relevant academic research and scientific papers
Synthesis of a naphthyridone p38 MAP kinase inhibitor
Chung, John Y. L.,Cvetovich, Raymond J.,McLaughlin, Mark,Amato, Joseph,Tsay, Fuh-Rong,Jensen, Mark,Weissman, Steve,Zewge, Daniel
, p. 8602 - 8609 (2007/10/03)
Compound 1 is a p38 MAP kinase inhibitor potentially useful for the treatment of rheumatoid arthritis and psoriasis. A novel six-step synthesis suitable for large-scale preparation was developed in support of a drug development program at Merck Research Laboratories. The key steps include a tandem Heck-lactamization, N-oxidation, and a highly chemoselective Grignard addition of 4-(N-tert-butylpiperidinyl)-magnesium chloride to a naphthyridone N-oxide. The N-oxide exerted complete chemoselectivity via chelation in directing the Grignard addition to the α position as opposed to 1,4-addition on the enelactam. The dihydropyridyl adduct was in situ aromatized with isobutylchloroformate followed by heating in pyridine. Syntheses of Grignard precursor, N-tert-butyl-4-chloro-piperidine, were accomplished via transamination with a quaternary ammonium piperidone or via addition of methylmagnesium chloride to an iminium ion. Utilizing this chemistry, multi-kilogram preparation of compound 1 was successfully demonstrated. American Chemical Society.
Efficient synthesis of a trisubstituted 1,6-naphthyridone from acetonedicarboxylate and regioselective Suzuki arylation
Chung, John Y. L.,Cai, Chaoxian,McWilliams, J. Christopher,Reamer, Robert A.,Dormer, Peter G.,Cvetovich, Raymond J.
, p. 10342 - 10347 (2007/10/03)
An efficient five-step synthesis of 1,6-naphthyridone 3b, a p38 mitogen-activated protein (MAP) kinase inhibitor intermediate, in 32% overall yield starting from acetonedicarboxylate (ADC) is described. The synthesis began with a selective monoamidation o
